Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oralgen Grass Pollen (brand name: Oralgen®) is a sublingual immunotherapy (SLIT) biologic developed by Artu Biologicals for the treatment of grass pollen-induced allergic rhinoconjunctivitis (hay fever). It is formulated as a standardized, glycerinated aqueous extract containing allergens from five specific grass species: *Lolium perenne* (perennial ryegrass), *Phleum pratense* (timothy grass), *Dactylis glomerata* (orchard grass), *Anthoxanthum odoratum* (sweet vernal grass), and *Holcus lanatus* (velvet grass). The product works by desensitizing the patient's immune system through allergen-specific immunotherapy, which modulates the IgE-mediated allergic response. Administration typically involves a 20-day dose escalation phase followed by a long-term maintenance phase (up to 2 years) to achieve sustained clinical benefit and immune tolerance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oralgen Grass Pollen.